UCLA Clinical Consortium Award - Clinical Research Site
Abstract
As a member of the Department of Defense Prostate Cancer Clinical Trials Consortium (PCCTC), UCLA has completed its second year as a member. We have opened and enrolled on existing PCCTC trials. Importantly, we have offered and opened one study that has already been activated in the PCCTC. We have offered 5 studies to the PCCTC, of which four are investigator initiated and have been funded by PCF Challenge Awards (n = 3) or an industry sponsor. These studies leverage the results from pre-clinical studies conducted at UCLA, including data generated from the UCLA SPORE and the Stand Up 2 Cancer West Coast Dream Team. The clinical trials offered to the PCCTC by UCLA directly address PCRP overarching challenges and focus areas. For example, our therapeutic intervention study of oligometastatic disease seeks to identify the molecular profile of primary tumors that ultimately metastasize and thereby distinguish aggressive from indolent disease in men newly diagnosed with prostate cancer. Insight into the drivers of metastasis could lead to the identification of actionable targets to prevent progression to lethal prostate cancer. In leveraging the discoveries generated from the SPORE, SU2C WCDT and other programs, our proposed trials promise to validate novel agents that target specific pathways and combinatorial treatments to improve the therapy of patients with advanced disease.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2017
- Accession Number
- AD1054785
Entities
People
- Matthew B Rettig
Organizations
- University of California, Los Angeles